Rheumatoid arthritis - adalimumab, etanercept and infliximab
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
| Guidance type: Technology appraisal |
| Date issued: October 2007 |
We will consult on our review plans for this guidance in September 2010. |
| Reference: TA130 |
SummaryThis guidance recommends adalimumab, etanercept and infliximab as possible treatments for people with rheumatoid arthritis who:
This guidance replaces TA36 'Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis' issued in March 2002. This review and re-appraisal has additionally included adalimumab for the treatment of rheumatoid arthritis, and has taken into account changes in the marketing authorisations for infliximab and etanercept. |
| Top |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
